GSK in breach for misleading prescription information on Omjjara, industry body says
- QUANTUNG PHARMA
- Apr 14
- 1 min read
April 15 (Reuters) - British pharmaceutical giant GSK (GSK.L)
, opens new tab has not met required ethical and regulatory standards in the marketing and prescription information for its Omjjara drug, an industry self-regulatory body said on Tuesday.
Omjjara is used to treat symptoms such as an enlarged spleen in adults with myelofibrosis - a rare bone marrow blood cancer - and moderate to severe anaemia.
